David. B. Goldstein

David. B. Goldstein

Auto-generated profile, based on publicly available information

David. B. Goldstein

Genomic & Bioinformatics Analysis Resource (GenBAR), Columbia University Medical Center, New York, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2017 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
SDSarah A. Dugger
Sarah A. Dugger
APAdam Platt
Adam Platt
DGDavid B. Goldstein
David B. Goldstein

14 July 2016 in Genome Biology
Verified
Journal Article
Open access
PDF file
SPSlavé Petrovski
Slavé Petrovski
DGDavid B. Goldstein
David B. Goldstein
An important application of modern genomics is diagnosing genetic disorders. We use the largest publicly available exome sequence database to show that this key clinical service can currently be performed much more effectively in individuals of European genetic ancestry.

15 September 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MMMohamad A Mikati
Mohamad A Mikati
YJYong‐Hui Jiang
Yong‐Hui Jiang
MCMichael Carboni
Michael Carboni
VSVandana Shashi
Vandana Shashi
SPSlave Petrovski
Slave Petrovski
DGDavid Goldstein
David Goldstein

11 October 2019 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
GPGundula Povysil
Gundula Povysil
SPSlavé Petrovski
Slavé Petrovski
JHJoseph Hostyk
Joseph Hostyk
VAVimla Aggarwal
Vimla Aggarwal
AAAndrew S. Allen
Andrew S. Allen
DGDavid B. Goldstein
David B. Goldstein

25 November 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
ACALSGENS Consortium
ALSGENS Consortium
SFSali Farhan
Sali Farhan
FCFALS Consortium
FALS Consortium
PCProject MinE Consortium
Project MinE Consortium
CCCReATe Consortium
CReATe Consortium
BNBenjamin M. Neale
Benjamin M. Neale

2 September 2015 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
SPSlavé Petrovski
Slavé Petrovski
AGAyal B. Gussow
Ayal B. Gussow
QWQuanli Wang
Quanli Wang
MHMatt Halvorsen
Matt Halvorsen
YHYujun Han
Yujun Han
DGDavid B. Goldstein
David B. Goldstein
Noncoding sequence contains pathogenic mutations. Yet, compared with mutations in protein-coding sequence, pathogenic regulatory mutations are notoriously difficult to recognize. Most fundamentally, we are not yet adept at recognizing the sequence stretches in the human genome that are most important in regulating the expression of genes. For this reason, it is difficult to apply to the regulatory regions the same kinds of analytical paradigms that are being successfully applied to identify mutations among protein-coding regions that influence risk. To determine whether dosage sensitive genes have distinct patterns among their noncoding sequence, we present two primary approaches that focus solely on a gene’s proximal noncoding regulatory sequence. The first approach is a regulatory sequence analogue of the recently introduced residual variation intolerance score (RVIS), termed noncoding RVIS, or ncRVIS. The ncRVIS compares observed and predicted levels of standing variation in the regulatory sequence of human genes. The second approach, termed ncGERP, reflects the phylogenetic conservation of a gene’s regulatory sequence using GERP++. We assess how well these two approaches correlate with four gene lists that use different ways to identify genes known or likely to cause disease through changes in expression: 1) genes that are known to cause disease through haploinsufficiency, 2) genes curated as dosage sensitive in ClinGen’s Genome Dosage Map, 3) genes judged likely to be under purifying selection for mutations that change expression levels because they are statistically depleted of loss-of-function variants in the general population, and 4) genes judged unlikely to cause disease based on the presence of copy number variants in the general population. We find that both noncoding scores are highly predictive of dosage sensitivity using any of these criteria. In a similar way to ncGERP, we assess two ensemble-based predictors of regional noncoding importance, ncCADD and ncGWAVA, and find both scores are significantly predictive of human dosage sensitive genes and appear to carry information beyond conservation, as assessed by ncGERP. These results highlight that the intolerance of noncoding sequence stretches in the human genome can provide a critical complementary tool to other genome annotation approaches to help identify the parts of the human genome increasingly likely to harbor mutations that influence risk of disease. Mutations in noncoding sequence can cause disease but are very difficult to recognize. Here, we present two approaches intended to help identify noncoding regions of the genome that may carry mutations influencing disease. The first approach is based on comparing observed and predicted levels of standing human variation in the noncoding exome sequence of a gene. The second approach is based on the phylogenetic conservation of a gene’s noncoding exome sequence using GERP++. We find that both approaches can predict genes known to cause disease through changes in expression level, genes depleted of loss-of-function alleles in the general population, and genes permissive of copy number variants in the general population. We find that both scores aid in interpreting loss-of-function mutations and in defining regions of noncoding sequence that are more likely to harbor mutations that influence risk of disease.